Use of omalizumab as adjuvant therapy in VIT

ReferenceStudy typeAllergenVIT protocolOmalizumab dose (mg)Timing of omalizumab administrationPatientsMain results/aimsAdverse events during omalizumab + VIT
Wedi et al. [21], 2007Case reportHoneybeeUltra-rush150One-time dose1VIT tolerance achieved after a single dose, even after the end of treatmentAbsent
Schulze et al. [22], 2007Case reportHoneybeeUltra-rush300One-time dose1VIT tolerance achieved after a single dose, even after the end of treatmentN.A.
Soriano Gomis et al. [20], 2008Case reportHoneybeeUltra-rush300Every 28 days1Failure to achieve VIT tolerancePatients showed anaphylaxis during the build-up phase
Averbeck et al. [23], 2008Case reportVespulaUltra-rush300Every 28 days1VIT tolerance achieved after a single dose, even after the end of treatmentAbsent
Rerinck et al. [24], 2008Case reportHoneybeeN.A.1502 doses at 14-days-interval before ultra-rush, then every 28–42 days1VIT tolerance achieved after a single dose, even after the end of treatmentAbsent
Galera et al. [25], 2009Case reportHoneybeeRush150Every 14 days1After lowering to 75 mg, anaphylaxis occurred, but 150 mg showed no more adverse reactionsAbsent
Kontou-Fili and Filis [26], 2009Case reportHoneybeeModified rush300Every 28 days1VIT tolerance achieved; anaphylaxis following decreased attemptAbsent
González-Pérez et al. [27], 2010Case reportHoneybeeN.A.300N.A.1VIT tolerance achieved; anaphylactic reaction followed omalizumab discontinuationAbsent
Palgan et al. [28], 2014Case reportVespulaRush150Every 28 days1VIT tolerance achievedAbsent
da Silva et al. [29], 2013Case reportHoneybeeUltra-rush300Every 28 days1VIT tolerance achieved, even after the end of treatmentAbsent
Boni et al. [30], 2016Case reportHoneybeeRush450Every 28 days1VIT tolerance achievedAbsent
Stretz et al. [31], 2017Case seriesHoneybee and VespulaRush and ultra-rushAccording to total IgE and body weightEvery 28 days10VIT tolerance achieved, even after the end of treatmentAbsent
Toldrá et al. [32], 2017Case reportHoneybeeRush300Every 14 days1VIT tolerance achieved; anaphylaxis after discontinuation attemptAbsent
Lourenço et al. [33], 2017Case reportHoneybeeUltra-rush300Every 14 days1VIT tolerance achievedAbsent
Lopes et al. [34], 2017Case reportHoneybeeN.A.450 or 300Every 28 days3VIT tolerance achievedAbsent
Yilmaz et al. [35], 2018Case reportHoneybeeConventional150Every 14 days1VIT discontinuationFacial erythema
Droitcourt et al. [36], 2019Case reportHoneybee or VespulaRushAccording to total IgE and body weightEvery 14 days3VIT tolerance achieved, even after the end of treatmentAbsent
Gülsen [37], 2021Case reportHoneybeeRush1505 weeks, 3 weeks, and 1 week prior to re-start of immunotherapy and for 2 months in parallel to VIT1Omalizumab is useful as a premedication in patients with mastocytosis who do not tolerate VITAbsent
Çetin et al. [38], 2022Retrospective studyHoneybee and VespulaRush and ultra-rush150Every 14 days

72 (total)

2 (VIT + omalizumab)

Omalizumab use as an add-on in OIT results in a strong premedication effect but not an immunomodulatory effect on VITAbsent

N.A.: not applicable; OIT: oral immunotherapy